近日,山东大学材料学院蒋妍彦团队在Advanced Science(IF=16.8 一区)杂志上发表了题为:“A Multifunctional Bimetallic Nanoplatform for Synergic Local Hyperthermia and Chemotherapy Targeting HER2-Positive Breast Cancer.”的文章,研究团队开发了一个纳米治疗平台,结合了双金属金银空心纳米壳、吡咯替尼和赫赛汀,实现了多...
Swain Sandra M,Shastry Mythili,Hamilton Erika. Targeting HER2-positive breast cancer: advances and future directions.[J]. Nature reviews. Drug discovery,2022. Mandó, P., Rivero, S. G., Rizzo, M. M., Pinkasz, M. & Levy, E. M....
[9] Yamaguchi K, Bang Y J, Iwasa S, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2–positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gas...
FINDINGS: In this phase 1 nonrandomized clinical trial of 66 patients with advanced-stage ERBB2-positive breast cancer, a majority grade 1/2 adverse events were generated for all doses. Patients in arms 2 (100 μg) and 3 (500 μg) had higher mag...
Endo Y, Dong Y, Kondo N, et al. HER2 mutation status in Japanese HER2-positive breast cancer patients. Breast Cancer. 2015;12:1-7. Fang Y, Jiang Y, Wang X, et al. Somatic mutations of the HER2 in metastatic breast cancer. Tumor Biol. 2014;35(12):11851-11854. ...
[10]Gorantla VC, Rui A, Rosenfeld SB, et al. Real-world data comparison of time to next treatment for patients with HER2 positive metastatic breast cancer treated in the second line of therapy with fam-trastuzumab deruxtecan-nxki or ado-trastuzumab emtansine. 2024 ASCO. e13025. ...
9. Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med 2020; 382(7):610-621. 10. Cortes J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, et al. Trastuzumab Deruxtecan versus ...
phenotypically positive tumors into phenotypically negative tumors. Therefore, we investigated the expression of the ICD in HER2-negative samples that overexpressed calpain-10. We found that 16% of HER2-negative tumors were positive for HER2-ICD, which was associated with circulating HER2-ECD. HER2 ...
[1] Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023 Feb;22(2):101-126. doi: 10.1038/s41573-022-00579-0. [2] Tebbutt, N., Pedersen, M. W....
从T-DXd布局的DESTINY-Breast系列研究到真实世界中的广泛应用,这一药物在HER2表达晚期乳腺癌治疗领域的重要地位得到了坚实的巩固,这无疑为HER2表达乳腺癌患者带来了更多希望,并提供了新的治疗路径。 史业辉 教授 天津医科大学肿瘤医院 乳腺肿瘤内科 科...